Skip to main content

TEVA

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

TEVA Price
Price Chart

Forward-looking statistics

Beta
1.03
Risk
49.20%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees38K
Market cap$19.1B

Fundamentals

Enterprise value$34.5B
Revenue$16.6B
Revenue per employee—
Profit margin-7.74%
Debt to equity270.20

Security info

ExchangeNyse American
Type of shareADR
Earnings per share (EPS)-$1.15
Dividend per share$0.34
Revenue per share$14.64
Avg trading volume (30 day)$175M
Avg trading volume (10 day)$155M
Put-call ratio—

Macro factor sensitivity

Growth+9.7
Credit-1.4
Liquidity-4.2
Inflation+6.6
Commodities+2.4
Interest Rates-1.1

Valuation

Dividend yield2.00%
PEG Ratio6.14
Price to sales1.17
P/E Ratio6.14
Enterprise Value to Revenue2.08
Price to book3.12

Upcoming events

Next earnings dayJuly 29, 2025
Next dividend day—
Ex. dividend dayNovember 27, 2017

News

TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.

Zacks Investment Research (July 11, 2025)
Why Is Teva Stock Trading Higher On Tuesday?

Teva Pharmaceutical Industries Ltd TEVA and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal lymphopoietin) and IL-13.

Benzinga (May 27, 2025)
Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties

Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, any pharma shortages in the U.S., and much more.

CNBC Television (May 7, 2025)
Teva Pharmaceuticals CEO talks Trump and US healthcare

Pharmaceutical companies brace for the upcoming Trump administration. Teva Pharmaceuticals (TEVA) CEO Richard Francis joins Seana Smith and Madison Mills on Catalysts to discuss what both the pharmaceutical company and industry at large are expecting from Trump's return to the White House.

Yahoo Finance (January 13, 2025)
Teva CEO on Drug Pricing, Generics, Supply Shortages

Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market, supply shortages of the drug Adderall, and selling GLP-1 drugs. He speaks to "Bloomberg Open Interest" from the JPMorgan Healthcare Conference.

Bloomberg Markets and Finance (January 13, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free